Choosing Third-Line Therapy
This is the second of two parts of the Latin America Regional Discussion Group held on the 8th of May 2025, available in English and Spanish.
Regional Expert
Dr Ana Inés Prado
CML Clinic at Maciel Hospital,
Montevideo, Uruguay
International Expert
Professor Michael Mauro
Leader, Myeloproliferative Neoplasms Program
Memorial Sloan Kettering Cancer Center
New York, USA
View the second part of this discussion group: Anticipating and managing acute TKI toxicity and adverse events
See all our 2025 Latin America Regional Discussion Groups on YouTube
Find all our Latin America Regional Discussion Groups on YouTube
Encuentra todos nuestros grupos de discusión en español en YouTube
00:00 Welcome and Introduction
05:18 Case 1: 59yo male develops neutropenia at day 15 of treatment
13:52 Discussion
24:55 Case 2: 61yo male with vomiting, worsening GERD, and spinal osteoarthritis
32:36 Discussion
